ICIs including CTLA-4 (ipilimumab), PD-1 (nivolumab or pembrolizumab), and PD-L1 (atezolizumab, avelumab, or durvalumab), either as a monotherapy or combination therapy can induce tumor responses in melanoma, non-small cell lung cancer (NSCLC), renal cell cancer (RCC), head and neck squamous cell carcinoma, urothelial cancer, breast cancer and Hodgkin disease (Ribas and Wolchok, 2018). Here, CTLA4 is linked to renal cell adenocarcinoma.